DP
TERN

Diadema Partners’s Terns Pharmaceuticals TERN Stock Holding History

Diadema Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,700
Closed -$2.61M – 203
2025
Q4 		$2.61M Sell
64,700
-160,500
-71% -$3.71M 0.45% 51
2025
Q3 		$1.69M Buy
225,200
+64,300
+40% +$411K 0.43% 67
2025
Q2 		$600K Buy
+160,900
New +$503K 0.18% 78

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Diadema Partners's TERN Position: Q1 2026 in Review

Diadema Partners reduced its Terns Pharmaceuticals (TERN) stake by 47% in Q1 2026, selling an estimated $6.74M and leaving 181,752 shares worth $9.58M. The position accounts for 1.63% of the portfolio, ranked #21.

Diadema Partners first reported a position in TERN in Q4 2024 and has held it in 6 quarters since. The position peaked at $14M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Diadema Partners held 181,752 shares of Terns Pharmaceuticals worth $9.58M as of Q1 2026.
  • Diadema Partners sold 164,128 Terns Pharmaceuticals shares in Q1 2026, an estimated $6.74M.
  • Terns Pharmaceuticals made up 1.63% of Diadema Partners's portfolio in Q1 2026, its #21 holding.
  • Diadema Partners first reported a position in Terns Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Diadema Partners's Terns Pharmaceuticals position peaked at $14M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.